DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

HOUSTON, Nov. 24, 2019 /PRNewswire/ -- DNAtrix, a leader in the development of oncolytic viruses for cancer therapy, today presented updated safety and efficacy data from the fully-enrolled Phase 2 CAPTIVE / KEYNOTE-192 study of DNX-2401 (tasadenoturev), DNAtrix's oncolytic adenovirus,...

from PR Newswire: https://ift.tt/2XG2wPk